Clinical Trial Update: A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating subcutaneous sirukumab (CNTO 136) in Japanese patients with active rheumatoid arthritis unresponsive to methotrexate or sulfasalazine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Sirukumab (sirukumab)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2016-10-27